Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%

Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis

Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.86 [0.8, 0.91]
4 studies · 606 participants
High

Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis

Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.68 [0.59, 0.78]
3 studies · 601 participants
Moderate

Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis

Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.82 [0.75, 0.91]
3 studies · 583 participants
High

Clinical relapse · Patients with moderately to severely active ulcerative colitis

Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.67 [0.59, 0.77]
1 study · 373 participants
Moderate

Endoscopic relapse · Patients with moderately to severely active ulcerative colitis

Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.58 [0.49, 0.68]
1 study · 373 participants
Moderate

Adverse events · Patients with moderately to severely active ulcerative colitis

Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 0.99 [0.93, 1.07]
2 studies · 941 participants
High

Serious adverse events · Patients with moderately to severely active ulcerative colitis

Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 1.01 [0.72, 1.42]
3 studies · 1122 participants
Moderate